2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
Zengin Z, Henderson N, Park J, Ali A, Nguyen C, Hwang C, Barata P, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer And Prostatic Diseases 2024, 1-7. PMID: 38383885, DOI: 10.1038/s41391-024-00805-3.Peer-Reviewed Original ResearchAndrogen receptor-targeted agentsCastration-resistant prostate cancerAR alterationsAR amplificationAR mutationsProstate cancerGene alterationsClinical outcomesAssociated with longer time to progressionCastration-resistant prostate cancer patientsGenomic testingLonger time to progressionTime to progressionAdvanced prostate cancerReceptor-targeted agentsPSA responseMetastatic diseaseOverall survivalMulti-institutional collaborative effortTestosterone suppressionMedian ageTargeted agentsProspective studyTreatment outcomesTherapeutic strategies
2022
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
Zengin Z, Henderson N, Park J, Ali A, Hwang C, Barata P, Bilen M, Graham L, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts). Journal Of Clinical Oncology 2022, 40: 138-138. DOI: 10.1200/jco.2022.40.6_suppl.138.Peer-Reviewed Original ResearchAR alterationsAR mutationsGenomic testingAdvanced prostate cancer patientsAndrogen receptor alterationsKaplan-Meier methodLog-rank testProstate cancer patientsAlteration statusMedian TTPPSA declineCastration resistancePSA responseMedian ageAR amplificationDocetaxel exposureReceptor alterationsStratified patientsTestosterone suppressionShorter TTPCancer patientsTreatment outcomesAbirateroneCastration statusDomain mutations